SLC5A2 and type 2 diabetes mellitus: Metformin, alfa-glucosidase inhibitors, thiazolidinediones, GLP1-receptor agonists, and SGLT2 inhibitors have proven efficacy in reducing the incidence of type 2 diabetes in subjects with prediabetes.